Myelodysplastic Syndrome (MDS)

Advanced Disease

Transfusion-dependent

Matched Related Donor

Matched Unrelated Donor

Haplo

BMT326
Phase III
Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancies

BMT330
Phase II/III
MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells

BMT338
Phase I
Donor Grafts Derived from OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies

PI: Meyer
NIH

HEMMD0036
Phase II Opi in Older vs Younger Adults Undergoing Allogeneic HCT for MDS
PI: Muffy
Sponsor: CIBMTR

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Extension Study
Immunotherapy
Link
Trial Posting
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu